• en
  • de

Convergys® Fib Clauss

Assay for the quantitative determination of fibrinogen in plasma.

The Fibrinogen assay using the Clauss method is the most widely used assay for the quantitative determination of the plasma fibrinogen concentration.
A highly concentrated thrombin is added to diluted plasma and the clotting time is used to determine the fibrinogen concentration in the sample.

  • The examination of fibrinogen levels using the Fib Clauss assay can be used as part of a general haemostatic screening in addition to APTT (activated partial thromboplastin time) and PT (prothrombin time) assays.
  • Convergys® Fib Clauss is used for the quantitative determination of fibrinogen in citrated plasma using to the Clauss technique. The patient’s plasma is diluted and subsequently thrombin is added to a high concentration. Fibrinogen is then rapidly cleaved to fibrin monomers which then polymerize and form a mesh.
  • The time until clotting is then given in seconds and compared with a calibration curve obtained by using a plasma sample with known fibrinogen concentration (reference plasma). The result of this comparison is given in g/l.
  • Specifications:
  • Sensitivity: linearity between 0.6 g/l and 8.0 g/l
  • Specificity: CV<6.5 % within and between runs (normal control)
  • Interfering substances: No interferences up to: Heparin 4 IU/ml, Bilirubin 50 mg/l, Dabigatran 475 μg/l, Triglycerides 3.75 g/l
  • Stability and storage conditions:
  • Shelf life: 24 months from the date of production at 2–8 °C
  • Reconstituted: 7 days at 2–25 °C
http://convergent-technologies.de/product/convergys-fib-clauss/